New CAR T therapy for relapsed and refractory ALL

Bookmark and Share
Published: 25 Jun 2020
Views: 537
Dr Claire Roddie - University College London, London, UK

Dr Claire Roddie speaks to ecancer in an online interview for the virtual EHA 2020 meeting.

She discusses the idea of a low toxicity CAR T which is now being trialled for relapsed/refractory acute lymphoblastic leukaemia.

Dr Roddie gives a thorough account of how the manufacturing takes place and how treatment is given.

She gives some preliminary results and toxicities, so far showing promise.